Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
暂无分享,去创建一个
Xiaojiao Li | Hong Zhang | Yanhua Ding | Cuiyun Li | Min Wu | Xiaoxue Zhu | Jixuan Sun | K. Chai | Xiaodi Zhang | Xiaoxue Zhu